June 25th 2025
Marketed as Orlynvah, oral sulopenem from Iterum Therapeutics was FDA approved last fall for uncomplicated urinary tract infections and has shown efficacy against infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis.
Gram-positive multidrug-resistant infections may be managed effectively with a single dose of long-acting lipo­glycopeptide antibiotics in the outpatient setting; however, careful patient selection is important for maximizing the cost-benefit of these relatively expensive drugs.
Read More
Gram-Negative Bacteria in Pneumonia Patients Demands Targeted Therapies
August 2nd 2018Gram-negative organisms are showing up at higher rates in seriously ill pneumonia patients. What are the best antibiotics to prescribe, given the real risk of death and the need to avoid contributing to drug resistance?
Read More